Enhancement of tumor radio-response by vinorelbine in vitro and vivo in mice lung tumor xenografts
Keywords:
lung adenocarcinoma, vinorelbine, radiotherapy, radiation enhancementAbstract
Objective: The aim of the experiment was to explore the optimal radioenhancement effect of vinorelbine on human lung adenocarcinoma. Methods: After combination treatment of 0.1 or 1nM vinorelbine with or without irradiation, cell viability was determined using clonogenic assays. Genotoxic potential of vinorelbine (NVB) and radiation (RT) alone, as well as in interaction, was determined in 973 cells using the alkaline comet assay. A male nude mouse lung tumor xenograft model was established by injecting 973 cells into nude mice. The nude mice were randomly divided into six groups: control group, 10Gy group, 20Gy group, vinorelbine group, vinorelbine + 10Gy group, vinorelbine + 20Gy group (n=8 mice per group). Vinorelbine was injected at 2 mg/kg. Tumors were measured every other day using vernier calipers. The tumor volume and growth delay were calculated. Enhancement factor (EF) was used to evaluate the radiation enhancement. Results: Vinorelbine had a significant effect on clonogenic survival in response to radiation in 973 cell lines at the higher dose of 1nM. The combination of vinorelbine and radiation caused a significant increase in tail moment compared to vinorelbine and radiation alone. Tumor growth inhibition in the vinorelbine + RT group was higher than in the radiation group or vinorelbine group (p < 0.05). The values of EF were 1.1 and 1.2, respectively. The longest time of tumor growth delay was 28 days in the vinorelbine + 20Gy group. Conclusions: Vinorelbine possesses radioenhancing properties for lung adenocarcinoma.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.